UNIVERSITY OF MELBOURNE

A new blood test can accurately diagnose celiac disease even in patients already following a gluten-free diet, eliminating the need for painful gluten challenges that worsen symptoms.

Researchers at the Peter Doherty Institute in Melbourne have developed a breakthrough method using mRNA technology to make HIV visible in white blood cells where it typically hides.

Proteomics International's PromarkerEndo blood test demonstrated nearly 90% accuracy in detecting early-stage endometriosis across a 704-participant study presented at the World Congress on Endometriosis.

Researchers at the University of Melbourne have developed a proteomic blood test that can analyze thousands of proteins to diagnose rare genetic diseases in children within three days, requiring only 1ml of blood from infants.

Glucotrack has received ethical approval from St. Vincent's Hospital Melbourne HREC for a year-long clinical study of its implantable continuous blood glucose monitor in patients with type 1 and type 2 diabetes.

A large, multi-center trial (ROCKet) is underway to assess if intravenous ketamine, administered perioperatively, can reduce chronic post-surgical pain (CPSP) at 3 months post-surgery.

Australia is seeking to simplify its clinical trial regulations to enhance efficiency and innovation in medical research.

A CRISPR-Cas13bt3 system, delivered via AAV, significantly reduced VEGFA mRNA and protein expression in human retinal organoids and VEGF-transgenic mouse models.

A new review suggests that fathers taking the epilepsy drug valproate do not pose a significant risk of birth defects or developmental disorders in their children.

A new study indicates that valproate, an anti-seizure medication, does not pose a significant risk of birth defects or developmental disorders when taken by men planning to father children.